Identification of protein clusters predictive of tumor response in rectal cancer patients receiving neoadjuvant chemo-radiotherapy
Metrics: PDF 1279 views | HTML 1705 views | ?
Ombretta Repetto1, Valli De Re1, Antonino De Paoli2, Claudio Belluco3, Lara Alessandrini4, Vincenzo Canzonieri4, Renato Cannizzaro5
1Facility of Bio-Proteomics, Immunopathology and Cancer Biomarkers, IRCCS CRO National Cancer Institute, Aviano, Italy
2Radiation Oncology, IRCCS CRO National Cancer Institute, Aviano, Italy
3Surgical Oncology, IRCCS CRO National Cancer Institute, Aviano, Italy
4Pathology, IRCCS CRO National Cancer Institute, Aviano, Italy
5Gastroenterology, IRCCS CRO National Cancer Institute, Aviano, Italy
Valli De Re, email: email@example.com
Keywords: DIGE, gastric diseases, rectal proteomics, rectal cancer, tumor regression grade
Received: August 29, 2016 Accepted: February 27, 2017 Published: March 09, 2017
Preoperative neoadjuvant chemoradiotherapy (nCRT) is the gold standard in locally advanced rectal cancer, only 10–30% of patients achieving benefits. Currently, there is a need of a reliable selection of markers for the identification of poor or non-responders prior to therapy. In this work, we compared protein profiles before therapy of patients differing in their responses to nCRT to find novel predictive markers of response to therapy. Patients were grouped into 3 groups according to their tumor regression grading (TRG) after surgery: 'TRG 1–2', good responders, 'TRG 3' and 'TRG 4', poor responders. Paired surgical specimens of rectal cancer and healthy (histologically confirmed) rectal tissues from 15 patients were analysed before nCRT by two dimensional difference in gel electrophoresis followed by mass spectrometry. Thirty spots were found as differentially expressed (p < 0.05). Among them, 3 spots (spots 471, 683 and 684) showed an increased amount of protein in poor responders compared with good responders, and they were more tumor associated compared with healthy tissues. Proteins of these spots were identified as fibrinogen ß chain fragment D, actin isoforms, B9 and B5 serpins, cathepsin D isoforms and peroxiredoxin-4. In an independent validation set of 20 rectal carcinomas we validated the increased fibrinogen ß chain abundance before nCRT in poor responders by immunoblotting. In conclusion, we propose a risk-stratification tool in predicting the response to nCRT treatment in rectal cancer based on the quantity of these proteins.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.